Patent foramen ovale

Shunichi Homma, Steven R. Messé, Tatjana Rundek, Yee Ping Sun, Jennifer Franke, Karina Davidson, Horst Sievert, Ralph L Sacco, Marco R. DI Tullio

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Patent foramen ovale (PFO) is the most common congenital heart abnormality of fetal origin and is present in approximately ∼25% of the worldwide adult population. PFO is the consequence of failed closure of the foramen ovale, a normal structure that exists in the fetus to direct blood flow directly from the right to the left atrium, bypassing the pulmonary circulation. PFO has historically been associated with an increased risk of stroke, the mechanism of which has been attributed to the paradoxical embolism of venous thrombi that shunt through the PFO directly to the left atrium. However, several studies have failed to show an increased risk of stroke in asymptomatic patients with a PFO, and the risk of stroke recurrence is low in patients who have had a stroke that may be attributed to a PFO. With the advent of transoesophageal and transthoracic echocardiography, as well as transcranial Doppler, a PFO can be routinely detected in clinical practice. Medical treatment with either antiplatelet or anticoagulation therapy is recommended. At the current time, closure of the PFO by percutaneous interventional techniques does not appear to reduce the risk of stroke compared to conventional medical treatment, as shown by three large clinical trials. Considerable controversy remains regarding the optimal treatment strategy for patients with both cryptogenic stroke and PFO. This Primer discusses the epidemiology, mechanisms, pathophysiology, diagnosis, screening, management and effects on quality of life of PFO.

Original languageEnglish (US)
Pages (from-to)1-15
Number of pages15
JournalNature Reviews Disease Primers
Volume2
DOIs
StatePublished - Jan 21 2016

Fingerprint

Patent Foramen Ovale
Stroke
Heart Atria
Paradoxical Embolism
Foramen Ovale
Pulmonary Circulation
Congenital Heart Defects
Transesophageal Echocardiography
Therapeutics
Echocardiography
Epidemiology
Fetus
Thrombosis
Quality of Life
Clinical Trials

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Homma, S., Messé, S. R., Rundek, T., Sun, Y. P., Franke, J., Davidson, K., ... DI Tullio, M. R. (2016). Patent foramen ovale. Nature Reviews Disease Primers, 2, 1-15. https://doi.org/10.1038/nrdp.2015.86

Patent foramen ovale. / Homma, Shunichi; Messé, Steven R.; Rundek, Tatjana; Sun, Yee Ping; Franke, Jennifer; Davidson, Karina; Sievert, Horst; Sacco, Ralph L; DI Tullio, Marco R.

In: Nature Reviews Disease Primers, Vol. 2, 21.01.2016, p. 1-15.

Research output: Contribution to journalArticle

Homma, S, Messé, SR, Rundek, T, Sun, YP, Franke, J, Davidson, K, Sievert, H, Sacco, RL & DI Tullio, MR 2016, 'Patent foramen ovale', Nature Reviews Disease Primers, vol. 2, pp. 1-15. https://doi.org/10.1038/nrdp.2015.86
Homma S, Messé SR, Rundek T, Sun YP, Franke J, Davidson K et al. Patent foramen ovale. Nature Reviews Disease Primers. 2016 Jan 21;2:1-15. https://doi.org/10.1038/nrdp.2015.86
Homma, Shunichi ; Messé, Steven R. ; Rundek, Tatjana ; Sun, Yee Ping ; Franke, Jennifer ; Davidson, Karina ; Sievert, Horst ; Sacco, Ralph L ; DI Tullio, Marco R. / Patent foramen ovale. In: Nature Reviews Disease Primers. 2016 ; Vol. 2. pp. 1-15.
@article{8d481c77634f412aa32a8d3f4d3421be,
title = "Patent foramen ovale",
abstract = "Patent foramen ovale (PFO) is the most common congenital heart abnormality of fetal origin and is present in approximately ∼25{\%} of the worldwide adult population. PFO is the consequence of failed closure of the foramen ovale, a normal structure that exists in the fetus to direct blood flow directly from the right to the left atrium, bypassing the pulmonary circulation. PFO has historically been associated with an increased risk of stroke, the mechanism of which has been attributed to the paradoxical embolism of venous thrombi that shunt through the PFO directly to the left atrium. However, several studies have failed to show an increased risk of stroke in asymptomatic patients with a PFO, and the risk of stroke recurrence is low in patients who have had a stroke that may be attributed to a PFO. With the advent of transoesophageal and transthoracic echocardiography, as well as transcranial Doppler, a PFO can be routinely detected in clinical practice. Medical treatment with either antiplatelet or anticoagulation therapy is recommended. At the current time, closure of the PFO by percutaneous interventional techniques does not appear to reduce the risk of stroke compared to conventional medical treatment, as shown by three large clinical trials. Considerable controversy remains regarding the optimal treatment strategy for patients with both cryptogenic stroke and PFO. This Primer discusses the epidemiology, mechanisms, pathophysiology, diagnosis, screening, management and effects on quality of life of PFO.",
author = "Shunichi Homma and Mess{\'e}, {Steven R.} and Tatjana Rundek and Sun, {Yee Ping} and Jennifer Franke and Karina Davidson and Horst Sievert and Sacco, {Ralph L} and {DI Tullio}, {Marco R.}",
year = "2016",
month = "1",
day = "21",
doi = "10.1038/nrdp.2015.86",
language = "English (US)",
volume = "2",
pages = "1--15",
journal = "Nature Reviews Disease Primers",
issn = "2056-676X",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Patent foramen ovale

AU - Homma, Shunichi

AU - Messé, Steven R.

AU - Rundek, Tatjana

AU - Sun, Yee Ping

AU - Franke, Jennifer

AU - Davidson, Karina

AU - Sievert, Horst

AU - Sacco, Ralph L

AU - DI Tullio, Marco R.

PY - 2016/1/21

Y1 - 2016/1/21

N2 - Patent foramen ovale (PFO) is the most common congenital heart abnormality of fetal origin and is present in approximately ∼25% of the worldwide adult population. PFO is the consequence of failed closure of the foramen ovale, a normal structure that exists in the fetus to direct blood flow directly from the right to the left atrium, bypassing the pulmonary circulation. PFO has historically been associated with an increased risk of stroke, the mechanism of which has been attributed to the paradoxical embolism of venous thrombi that shunt through the PFO directly to the left atrium. However, several studies have failed to show an increased risk of stroke in asymptomatic patients with a PFO, and the risk of stroke recurrence is low in patients who have had a stroke that may be attributed to a PFO. With the advent of transoesophageal and transthoracic echocardiography, as well as transcranial Doppler, a PFO can be routinely detected in clinical practice. Medical treatment with either antiplatelet or anticoagulation therapy is recommended. At the current time, closure of the PFO by percutaneous interventional techniques does not appear to reduce the risk of stroke compared to conventional medical treatment, as shown by three large clinical trials. Considerable controversy remains regarding the optimal treatment strategy for patients with both cryptogenic stroke and PFO. This Primer discusses the epidemiology, mechanisms, pathophysiology, diagnosis, screening, management and effects on quality of life of PFO.

AB - Patent foramen ovale (PFO) is the most common congenital heart abnormality of fetal origin and is present in approximately ∼25% of the worldwide adult population. PFO is the consequence of failed closure of the foramen ovale, a normal structure that exists in the fetus to direct blood flow directly from the right to the left atrium, bypassing the pulmonary circulation. PFO has historically been associated with an increased risk of stroke, the mechanism of which has been attributed to the paradoxical embolism of venous thrombi that shunt through the PFO directly to the left atrium. However, several studies have failed to show an increased risk of stroke in asymptomatic patients with a PFO, and the risk of stroke recurrence is low in patients who have had a stroke that may be attributed to a PFO. With the advent of transoesophageal and transthoracic echocardiography, as well as transcranial Doppler, a PFO can be routinely detected in clinical practice. Medical treatment with either antiplatelet or anticoagulation therapy is recommended. At the current time, closure of the PFO by percutaneous interventional techniques does not appear to reduce the risk of stroke compared to conventional medical treatment, as shown by three large clinical trials. Considerable controversy remains regarding the optimal treatment strategy for patients with both cryptogenic stroke and PFO. This Primer discusses the epidemiology, mechanisms, pathophysiology, diagnosis, screening, management and effects on quality of life of PFO.

UR - http://www.scopus.com/inward/record.url?scp=85019438676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019438676&partnerID=8YFLogxK

U2 - 10.1038/nrdp.2015.86

DO - 10.1038/nrdp.2015.86

M3 - Article

C2 - 27188965

AN - SCOPUS:85019438676

VL - 2

SP - 1

EP - 15

JO - Nature Reviews Disease Primers

JF - Nature Reviews Disease Primers

SN - 2056-676X

ER -